MarginsXMarginsX
Home › Markets › BCLI

Brainstorm Cell Therapeutics Inc. (BCLI)

BCLI is quoted over the counter, not listed on an exchange. Brainstorm Cell Therapeutics Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.9000
-9.1% on the day
1-year return
+47.5%
Market cap
$9.9M
Nano cap. From the Nov 16, 2026 close × 11M shares (10-Q cover page, Aug 11, 2026)
P/E and P/S
Net loss over the period · No revenue line filed
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerBCLI, quoted over the counter
SEC CIK0001137883
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codeBiological Products, (No Diagnostic Substances)
Business addressNew York, NY
Incorporated inDE

Warning signs

Cash runway
0.1 months
$22K cash at June 30, 2026
Share count, 1 year
+6.3%
2025-08-11 to 2026-08-11 · +267.7% over 3 years
Going-concern doubt
No
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-14
Cash and burn$22K cash; operating cash flow -$1.0M a quarter.Report 2026-06-30
Shares outstanding11,034,775 (2026-08-11); 10,376,109 a year earlier; 45,015,800 three years earlier. 3y figure adjusted for splits (1-for-15 overall).Cover page 2026-08-11
Reverse splits, 3 years1; latest 1-for-15 on 2024-10-01Source 2024-10-01
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2025-10-09
AuditorBrightman Almagor Zohar & Co., Tel Aviv, IsraelPCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.9M-$895K$22K$1.3MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$2.1M-$1.3M$15K$1.3MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$2.4M-$740K$29K$967KNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$2.1M-$1.1M$5K$101KNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$2.9M-$3.5M$824K$101KNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$2.9M-$1.6M$1.6M$1.2MNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$3.0M-$1.0M$187K$300KNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$2.7M-$3.3M$168KNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-05-21
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-11-16
Latest proxyDEFA14A2025-05-16

Source: SEC EDGAR submissions feed, 950 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier